Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration.
Summary
Bill A00265 aims to enhance the availability of opioid reversal agents, specifically by requiring the New York State Department of Health to maintain a publicly accessible directory of distributors. This directory will include information such as addresses, contact details, services offered, and available opioid reversal agents. The bill also mandates that the department covers the costs of any FDA-approved nasal naloxone product, while any additional costs for higher-priced products will be the responsibility of the purchaser. Furthermore, it allows for the choice of any formulation and dosage of opioid reversal agents approved by the FDA.
Impact
The bill will amend the mental hygiene law and public health law in New York, thereby expanding the accessibility and distribution of opioid reversal agents. This is expected to improve the response to opioid overdoses by ensuring that more entities, such as community organizations and pharmacies, can access these life-saving medications. The establishment of a searchable directory will also facilitate easier access for individuals and organizations seeking these agents, potentially leading to better public health outcomes.
Sentiment
The sentiment surrounding Bill A00265 appears to be overwhelmingly positive, as evidenced by the unanimous support in committee votes and the final passage in the Assembly. The discussions have focused on the importance of addressing the opioid crisis and ensuring that reversal agents are readily available to those in need, reflecting a strong consensus on the necessity of the bill.
Contention
While there seems to be broad support for the bill, potential points of contention could arise regarding the financial implications for purchasers of higher-priced opioid reversal agents, as they will bear the cost overruns. Additionally, discussions may surface around the effectiveness of the directory and whether it will adequately serve the needs of communities, particularly in underserved areas.
Same As
Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agents approved by the federal food and drug administration.